“…The clinical equivalence in terms of oncological integrity, fast track protocol compliance, PROs, survival benefits and MIS reproducibility have been established in the index GIM [17,18]. Assimilation of Pancreaticoduodenectomy (PD) into MIS repertoire has been slow as evident from reports of only 4% PDs being done by MIS, in decade long US data base volume of more than 15,000 PDs [19]. Apart from the 'learning proficiency curve' (LCP) issues, this slow adoption of minimally invasive PDs (MIPD) is attributable to the retroperitoneal location of pancreas, its proximity to major vessels, prevalence of aberrant major vessels, and propensity for major postoperative complication [19].…”